share_log

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9

Benzinga ·  Nov 14, 2023 09:32

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $43 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment